0.42
+18.31%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Biotech Services Holdings
Its shares trade on HKEX under the ticker 8037.HK. It has been listed since 17 June 2004. In the fiscal year to 31 December 2025, it reported revenue of HK$73.5m and a net loss of HK$68.8m. At that date it held total assets of HK$702.6m and shareholders' equity of HK$191.4m.
China Biotech Services Holdings Ltd. operates as an investment company, which engages in the provision of medical laboratory testing, and health check services. The company employs 180 full-time employees The company went IPO on 2004-06-17. The firm operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 17 Jun 2004
- Employees
- 180
- Website
- cbshhk.com ↗
Leadership
Pay as last reported
- Mr. Xiaolin LiuExecutive Chairman of the Board, Chief Compliance Officer, since 2017
- Mr. Xun HeExecutive Director, since 2018HK$2.2m
- Mr. Song HuangExecutive Director, since 2017HK$831,000
- Ms. Miu Shun WongCompany SecretaryHK$5.0m
- Dr. Yuantao GuoIndependent Non-Executive Director
- Mr. Hongji QianNon-Executive Independent DirectorHK$240,000
- Mr. Guoxiang YanNon-Executive Independent DirectorHK$240,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- 180 employees provide efficient medical laboratory testing services in HK.
- Six business segments ensure diversified revenue streams across Health Care.
- Immunotherapy segment offers innovative tumor immune cell therapy services.
Weaknesses
- Insurance Brokerage segment relies on external partnerships for brokerage services.
- Pharmaceutical Products segment faces high R&D costs for health-related products.
- Securities segment's trading activities are subject to market volatility.
Opportunities
- Growth in Health Care sector drives demand for medical laboratory services.
- Immunotherapy segment can expand with rising cancer treatment needs.
- HK's position as a financial hub supports Securities segment growth.
Threats
- Regulatory changes in HK may impact Insurance Brokerage segment operations.
- Competition in Pharmaceutical Products segment could reduce profit margins.
- Economic downturns affect Securities segment trading volumes significantly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.